Genexine said Friday that it would start developing GX-170, a next-generation DNA vaccine preventing tuberculosis, in joint efforts with Yonsei University. 

Genexine will start developing a next-generation DNA vaccine preventing tuberculosis, GX-170, in joint efforts with Yonsei University. (Genexine)
Genexine will start developing a next-generation DNA vaccine preventing tuberculosis, GX-170, in joint efforts with Yonsei University. (Genexine)

The company has secured candidate materials for the tuberculosis vaccine and completed its patent application, with the support of Yonsei University’s tuberculosis team, led by Professor Cho Sang-nae of the Department of Medicine, who have participated from the early stage of development. 

The company expects to start clinical trials soon based on the experience and know-how in developing the Covid-19 vaccine, GX-19N, Genexine said.

Tuberculosis is a bacterial disease that spreads through the air to the respiratory system. About 30 percent of people who have close contacts are infected without symptoms, and 10 percent suffer from it throughout their lives. 

Korea is most vulnerable to tuberculosis among OECD countries, with about 2,200 deaths from tuberculosis a year. The government recommends Bacillus Calmette–Guérin (BCG) vaccines for all newborns. There are no preventative injections for adults, either, other than BCG.

“We expect GX-170, a DNA-based vaccine, will replace BCG, as its animal testing confirmed its prevention efficacy,” a Genexine official said. “DNA vaccines are the most effective vaccine platform for preventing tuberculosis, and GX-170 can be used either alone or as a booster for existing BCG vaccines.”
 

Copyright © KBR Unauthorized reproduction, redistribution prohibited